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Abstract
Low antihypertensive medication adherence is common. Over recent years, the impact of low 
medication adherence on increased morbidity and healthcare costs has become more recognized, 
leading to interventions aimed at improving adherence. We analyzed a 5% sample of Medicare 
beneficiaries initiating antihypertensive medication between 2007 and 2012 to assess whether 
reductions occurred in discontinuation and low adherence. Discontinuation was defined as having 
no days of antihypertensive medication supply for the final 90 days of the 365 days following 
initiation. Low adherence was defined as having a proportion of days covered <80% during the 
365 days following initiation among beneficiaries who did not discontinue treatment. Between 
2007 and 2012, 41,135 Medicare beneficiaries in the 5% sample initiated antihypertensive 
medication. Discontinuation was stable over the study period (21.0% in 2007 and 21.3% in 2012; 
p-trend=0.451). Low adherence decreased from 37.4% in 2007 to 31.7% in 2012 (p-trend<0.001). 
After multivariable adjustment, the relative risk of low adherence for beneficiaries initiating 
treatment in 2012 versus in 2007 was 0.88 (95% confidence interval 0.83–0.92). Low adherence 
was more common among racial/ethnic minorities, beneficiaries with Medicaid buy-in (an 
indicator of low income), and those with polypharmacy, and was less common among females, 
beneficiaries initiating antihypertensive medication with multiple classes or a 90 day prescription 
fill, with dementia, a history of stroke, and those who reached the Medicare part D coverage gap in 
the previous year. In conclusion, low adherence to antihypertensive medication has decreased 
among Medicare beneficiaries however rates of discontinuation and low adherence remain high.
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Introduction
The majority of older US adults have hypertension.1 Despite the availability of effective 
antihypertensive medication, the prevalence of uncontrolled blood pressure (systolic/
diastolic blood pressure ≥ 140/90 mm Hg) among older adults with hypertension is high.2 
According to the National Health and Nutrition Examination Survey (NHANES) 2011–
2012, 38% of US adults ≥ 60 years of age with hypertension who were taking 
antihypertensive medication had uncontrolled blood pressure.2
Low adherence to antihypertensive medication is common and a major contributing factor to 
uncontrolled blood pressure, excess healthcare costs, and increased risk for cardiovascular 
disease (CVD) events among adults with hypertension.3, 4 The importance of medication 
adherence was noted as early as the second Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC), published in 1980.5 
Over the past several decades, there have been “calls to action” to address the high incidence 
of discontinuation and low adherence to medications,3, 4, 6–8 and a number of randomized 
controlled trials evaluating interventions to improve adherence to antihypertensive 
medication have been conducted.3, 4, 8 Meta-analysis of these interventions suggest many are 
efficacious.9–11 However, there is limited consensus as to what types of interventions are 
superior, and it is unclear whether they have been translated into improvements in adherence 
among patients in clinical practice. The purpose of this study was to evaluate secular trends 
in antihypertensive medication discontinuation and low adherence among Medicare 
beneficiaries initiating treatment between 2007 and 2012. Also, we identified 
sociodemographic characteristics and comorbid conditions associated with antihypertensive 
medication discontinuation and low adherence which may be useful for guiding the 
development of future adherence interventions.
Methods
We conducted a retrospective cohort study of Medicare beneficiaries initiating 
antihypertensive medication between 2007 and 2012 using data from a 5% random sample 
of beneficiaries. Medicare is a federally funded insurance program that provides healthcare 
coverage to US adults 65 years of age and older, who are disabled, or with end-stage renal 
disease. De-identified data on Medicare beneficiaries, including inpatient, outpatient, and 
prescription drug claims, were obtained from the Centers for Medicare and Medicaid 
Services (CMS). Use of these data was approved by CMS and by the University of Alabama 
at Birmingham Institutional Review Board.
Initiation was defined by the first claim for antihypertensive medication between 2007 and 
2012. To ensure complete data capture for defining antihypertensive medication initiation 
and adherence, we restricted the analyses to beneficiaries with inpatient (Medicare Part A), 
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outpatient (Medicare Part B) and pharmacy (Medicare Part D) coverage from the 365 days 
prior to their first antihypertensive medication fill during the study period (i.e., look-back 
period) to 365 days following initiation (i.e., follow-up period). As Medicare claims are not 
complete for beneficiaries with Medicare Part C coverage (Medicare Advantage), 
beneficiaries who had Part C coverage at any point during the look-back or follow-up period 
were excluded from all analyses. To confirm that beneficiaries were not prevalent users of 
antihypertensive medication, we restricted our analyses to beneficiaries with no claims for 
antihypertensive medication fills during the look-back period. To increase the likelihood that 
the antihypertensive medication was being used to lower blood pressure, we required 
beneficiaries to have ≥ 2 outpatient claims linked to physician evaluation and management 
codes, ≥ 7 days apart, with International Classification of Diseases, 9th Revision (ICD-9) 
diagnoses of 401.x (malignant, benign or unspecified essential hypertension) during the 
look-back period. We excluded beneficiaries who were < 65 years of age at the start of the 
365 day look-back period as these beneficiaries are not representative of the general 
Medicare population.
Antihypertensive medication fills
We identified prescription antihypertensive medication fills using claims in the Medicare 
Part D file. Antihypertensive medication classes included aldosterone receptor antagonists, 
alpha blockers, angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor 
blockers (ARB), beta blockers (BB), calcium channel blockers (CCB), central acting agents, 
direct vasodilators, diuretics (thiazide, loop, and potassium-sparing, separately), and renin 
inhibitors. All antihypertensive medication classes filled within 7 days of the first claim for 
antihypertensive medication (index fill), were considered as part of a beneficiary’s initial 
treatment regimen. Beneficiaries were further categorized as initiating antihypertensive 
treatment with a single class, multiclass/multiple pill, or multiclass/combination therapy. 
Combination therapy was defined as initiating treatment with one pill containing multiple 
antihypertensive classes.
Outcomes
Discontinuation was defined as having no days of antihypertensive medication available to 
take during the final 90 days of the 365 days following treatment initiation.12 
Antihypertensive medication adherence was calculated by assessing the interval-based 
proportion of days covered (PDC).13 The PDC was calculated using the number of days for 
which medication was available to take during the 365 days following initiation as the 
numerator and 365 days as the denominator (Figure 1, Top Panel).13, 14 For beneficiaries 
who filled more than one class of antihypertensive medication in the 365 days following 
initiation, we calculated the PDC counting days with any medication available to take in the 
numerator and 365 days as the denominator (Figure 1, Bottom Panel). Low adherence was 
defined by a PDC < 80%.13, 14 A PDC < 80% has been associated with increased mortality 
risk15 and is the convention for studies of adherence to antihypertensive medication.3, 13, 16
Covariates
We selected covariates, a priori, including age, sex, race/ethnicity, dementia, depression, 
diabetes, coronary heart disease (CHD), stroke, chronic kidney disease (CKD), heart failure 
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(HF), a serious fall injury, polypharmacy, initiating antihypertensive medication with a 90 
day prescription, and entering the Medicare Part D coverage gap. Polypharmacy was defined 
as having fills for ≥10 different medications. We also used Medicaid buy-in, payments of 
Medicare premiums by Medicaid, as a marker of low-income status. We utilized previously 
published algorithms and claims data to define these covariates during the look-back period 
(Table S1). We also separately assessed incident co-morbid conditions and having Medicaid 
buy-in, polypharmacy, and entering the Medicare Part D coverage gap during the 182 days 
following initiation, as development of these factors may influence medication taking 
behavior.
Statistical analyses
We calculated characteristics of beneficiaries initiating antihypertensive medication in each 
calendar year from 2007 through 2012. For each year, we also calculated the percentage of 
beneficiaries who discontinued antihypertensive medication and, among those who did not 
discontinue treatment, had low adherence in the 365 days following initiation. 
Discontinuation and low adherence were calculated for the overall population and in 
subgroups defined by age (66–69, 70–74, 75–79, 80–84, ≥85 years), sex, race/ethnicity 
(white, black, Hispanic, Asian, other), antihypertensive medication classes initiated, and 
initiating treatment with multiple drug classes or a 90 day prescription. We assessed linear 
trends across calendar year using Poisson regression for dichotomous variables and analysis 
of variance for continuous variables.
Next, we calculated risk ratios (RR) for antihypertensive medication discontinuation and, 
separately, low adherence associated with calendar year of initiation and the variables listed 
in the study covariates section above. After calculating unadjusted RRs, we conducted a 
second model including multivariable adjustment for all variables in the look-back period 
simultaneously. We also conducted a third multivariable model adjusting for all variables in 
the second model and variables from the 182 days following antihypertensive medication 
initiation as described above. To avoid co-linearity, each antihypertensive medication class 
was evaluated in separate regression models with beneficiaries initiating an antihypertensive 
medication class being compared to beneficiaries initiating treatment without that class.
We conducted several sensitivity analyses. First, we required beneficiaries to have ≥ 1 claim, 
versus ≥ 2 claims in the main analyses, for a diagnosis of hypertension in the look-back 
period. Second, we defined discontinuation as having no antihypertensive medication 
available to take during the final 60 days, versus 90 days in the main analysis, of follow-up. 
Third, we restricted the population to beneficiaries without a history of CHD, HF, diabetes 
or CKD because beneficiaries with these conditions may be prescribed antihypertensive 
medication for reasons other than hypertension. Fourth, as loop diuretics are often used for 
reasons other than hypertension, we excluded loop diuretics as an antihypertensive 
medication. Fifth, we excluded beneficiaries who had a claim for a skilled nursing facility 
stay during the look-back or follow-up period from analyses since these beneficiaries may 
have incomplete pharmacy claims. For low adherence, we also included a sixth sensitivity 
analysis using the prescription-based PDC method.13 In a final analysis, we calculated the 
percentage of beneficiaries who discontinued antihypertensive medication or had low 
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adherence, pooled together, utilizing the interval-based PDC calculation in each calendar 
year. The RR of discontinuation or low adherence pooled together over calendar years was 
also calculated. All analyses were conducted using SAS software version 9.3 (SAS Institute, 
Cary, NC).
Results
Between 2007 and 2012, we identified 41,135 Medicare beneficiaries in the 5% sample who 
met the eligibility criteria for the current analysis and initiated antihypertensive medication. 
Across the years studied, the mean age of beneficiaries initiating antihypertensive 
medication ranged from 75.9 to 76.7 years (Table 1). The percentage of those who initiated 
antihypertensive medication that were men and white increased between 2007 and 2012. The 
percentage of beneficiaries initiating antihypertensive medication with thiazide diuretics or 
combination therapy decreased. Initiation of prescriptions with a 90 day supply nearly 
doubled over the study time frame. A prior diagnosis of diabetes, CHD, CKD, depression, 
and polypharmacy increased, while Medicaid buy-in decreased, between 2007 and 2012.
Antihypertensive medication discontinuation
Among beneficiaries initiating antihypertensive medication in 2007, 21.0% discontinued 
treatment compared with 21.3% in 2012 (Figure 2; p-trend across calendar years 0.451). The 
percentage of beneficiaries who discontinued treatment decreased among those 70–74 years 
old and increased among beneficiaries ≥ 85 years old (Table S2). There were no secular 
trends in antihypertensive medication discontinuation by sex, race/ethnicity, and with the 
exception of ARBs, antihypertensive drug class initiated. Among Medicare beneficiaries 
initiating antihypertensive medication with an ARB, 21.1% in 2007 discontinued treatment 
compared with 17.2% in 2012 (p-trend=0.011).
After multivariable adjustment, women were less likely to discontinue antihypertensive 
medication compared with men while blacks, Hispanics, and Asians were more likely to 
discontinue treatment compared with white beneficiaries (Table 2). Initiation of 
antihypertensive medication with a CCB, ACE-I, ARB, BB, multiclass regimen, and a 90 
day prescription fill, and a history of stroke or dementia in the look-back period were 
associated with a lower risk of discontinuation. Beneficiaries who had Medicaid buy-in, a 
serious fall injury, or were on polypharmacy in the year prior to initiating antihypertensive 
medication had a higher risk of discontinuation. Incident diagnoses of stroke, HF, 
polypharmacy, and reaching the Medicare Part D coverage gap in the six months after 
initiation were associated with lower risk of discontinuation.
Low adherence to antihypertensive medication
The percentage of Medicare beneficiaries with low adherence to antihypertensive medication 
in the year after initiation decreased overall from 37.4% in 2007 to 31.7% in 2012 (Figure 2; 
p-trend <0.001). The percentage with low adherence to antihypertensive medication 
decreased over time among beneficiaries < 85 years old, men and women, and white and 
black beneficiaries (Table S3). After multivariable adjustment, low adherence declined 
between 2007 and 2012 (Table 3). Women were less likely than men to have low adherence 
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while black, Hispanic, Asian, and those of other race/ethnicities were more likely to have 
low adherence compared to white beneficiaries. Initiation of antihypertensive treatment with 
a CCB, ACE-I, BB, a multiclass regimen, and a 90 day prescription fill were associated with 
decreased risk for low adherence. Beneficiaries who had Medicaid buy-in, diabetes, CHD, 
CKD, and who were on polypharmacy in the year prior to initiation were more likely to have 
low adherence while those with dementia, a history of stroke, and Medicare coverage gap in 
the year prior to initiation were less likely to have low adherence. Polypharmacy and 
reaching the Medicare Part D Coverage Gap in the six months after initiation was associated 
with a decreased risk of low adherence while having a serious fall in the six months after 
initiation was associated with a higher risk of low adherence.
Sensitivity analysis
There were no statistically significant changes in the percentage of beneficiaries who 
discontinued antihypertensive medication between 2007 and 2012 in any of the sensitivity 
analyses (Table S4). The percentage of beneficiaries with low adherence decreased between 
2007 and 2012 in each of the sensitivity analyses (Table S5). The percentage of beneficiaries 
who discontinued or had low adherence to antihypertensive medication in the year after 
initiation decreased from 50.6% in 2007 to 46.2% in 2012 (Figure 2; Table S6; p-trend 
<0.001).
Discussion
In the current study of Medicare beneficiaries initiating antihypertensive medication, 
approximately 20% discontinued treatment within one year and this percentage remained 
constant between 2007 and 2012. In contrast, a decline in low adherence to antihypertensive 
medication occurred over this time period. However, in 2012, almost 50% of beneficiaries 
either discontinued antihypertensive medication or had low adherence in the year following 
treatment initiation.
Previous studies have suggested that treatment discontinuation is an intentional action while 
low adherence involves both intentional actions and unintentional behaviors.3, 17–19 Patients 
who discontinue antihypertensive medication report more side effects and cite concerns 
about medication as high relative to their need for treatment.17–19 These barriers may be 
difficult to overcome to keep patients on treatment. In contrast, some barriers to achieving 
high adherence can be overcome.17–19 For example, patient-centered care, including 
improved patient/provider communication and patient education has been associated with 
increased medication adherence.4, 20 It has been reported that healthcare has become more 
patient-centered over the past decade.21, 22 Also, a number of studies have reported 
interventions aimed at improving adherence prior to and during the time frame of this study, 
with some being effective.3, 4, 6–11 The translation of these interventions into clinical 
practice may explain some of the reduction in low adherence observed in the current study.
Black and Hispanic beneficiaries were more likely to discontinue and have low adherence to 
antihypertensive medication compared with whites, which is consistent with prior 
studies.23, 24 Cost has been cited as the largest barrier to antihypertensive medication 
adherence among blacks and Hispanics in the United States.23, 24 In previous studies, 
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reductions in copayments for antihypertensive medication have been associated with an 
increase in adherence.25, 26 Patient-provider trust has also been reported as a barrier to 
antihypertensive medication adherence among racial/ethnic minorities in the US.27 Building 
trust between physicians and patients through improved communication and race concordant 
physician/patient pairings has been shown to improve antihypertensive medication 
adherence, and these may be useful approaches to decreasing disparities in adherence.28 
Given the association between low adherence to antihypertensive medication and increased 
CVD risk and an approximately 30% higher risk for CVD mortality among blacks compared 
with whites, improving medication adherence among black adults should be a priority.1, 3, 4
Initiating antihypertensive medication treatment with an ARB was associated with a lower 
risk for discontinuation. Risk of discontinuation of ARBs was also lower in an analysis of 
the Marketscan® database for patients initiating treatment in 2001 through 2003, and can 
potentially be explained by lower rates of side effects for ARBs compared with other 
antihypertensive drug classes.29 Initiating treatment with a 90 day prescription fill became 
more common between 2007 and 2012 and was associated with decreased risk of 
discontinuation and low adherence. Longer prescription fills may help beneficiaries 
circumvent patient-system barriers to adherence including limited access to a 
pharmacy.30, 31
Medicaid buy-in and polypharmacy in the year prior to initiating antihypertensive 
medication were associated with a higher risk of both discontinuation and low adherence. 
Although beneficiaries with Medicaid buy-in receive assistance in paying for their 
healthcare utilization and medications, these patients are still subject to copayments and cost 
may be a barrier to achieving high adherence.24, 32 Also, recent studies have shown high out-
of-pocket expenses associated with polypharmacy, and the need for multiple medications 
can result in patients choosing to take some medications but not others.33 Interventions that 
reduce copayments for chronic disease medications, including antihypertensive medication, 
antidiabetes drugs, and statins, have demonstrated overall improvements in adherence and 
may be useful in reducing the need for patients to choose between drugs.25, 26 Incident 
polypharmacy and entering the Medicare Part D coverage gap during follow-up were 
associated with decreased risk of antihypertensive medication discontinuation. 
Polypharmacy and entering the Medicare Part D coverage gap during follow-up are likely 
markers of beneficiaries who are filling their medication.24
A serious fall injury during the look-back period was associated with an increased risk for 
antihypertensive medication discontinuation and a serious fall injury in the 6 months 
following initiation was associated with low antihypertensive medication adherence. Side 
effects of antihypertensive medication including dizziness and syncope could contribute to 
patients’ worries over fall risk.32 Although antihypertensive medication has been associated 
with an increased fall risk in previous studies, the risk attributable to antihypertensive 
treatment is low.34 In the Systolic Blood Pressure Intervention Trial, intensive versus 
standard BP treatment (systolic blood pressure <120 mm Hg vs. systolic blood pressure 
<140 mm Hg) was not associated with an increased risk for serious fall injuries.35, 36 
Additionally, the risk for falls can be mitigated by interventions including multiple risk 
factor assessment, physical therapy, and exercise.37
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Beneficiaries with a history of diabetes, CKD, and CHD were more likely to have low 
antihypertensive medication adherence. These populations may encounter several barriers to 
maintaining high antihypertensive medication adherence including low income, a high 
prevalence of depression, and complex medication-taking regimens including 
polypharmacy.38 Given the high CVD risk among adults with diabetes, CKD and CHD, 
identifying the barriers preventing antihypertensive medication adherence and developing 
interventions to improve adherence in patients with these comorbidities are needed. A 
history of dementia and stroke were associated with a lower risk of both discontinuation and 
low adherence. Many patients with dementia or a history of stroke have caregivers, which 
has been associated with better medication adherence.39, 40
The current study has several strengths. Medicare provides high generalizability to older US 
adults.41 The large sample size allowed us to study trends in medication adherence over time 
in sub-groups. The longitudinal data in Medicare made it possible to study adults initiating 
antihypertensive medication, and also allowed us to evaluate incident development of co-
morbid conditions and other characteristics during the 182 days following initiation of 
antihypertensive medication. Despite these strengths, this study should be interpreted in the 
context of its potential limitations. First, while Medicare data was available through 2013, as 
a result of requiring 365 days of follow-up to calculate discontinuation and low adherence 
following initiation of antihypertensive medication, we were only able to present results for 
beneficiaries who initiated treatment through December 31, 2012. Second, pharmacy fill 
data only provide an indirect measure of adherence and we cannot be certain the medication 
that Medicare beneficiaries filled was consumed. Also, it is possible that some beneficiaries 
purchased antihypertensive medication out-of-pocket or through alternate health plans 
without submitting claims for reimbursement through Medicare. If this occurred, the 
percentage of beneficiaries who discontinued treatment or had low adherence would be 
lower than we report. However, paying for medications without submitting claims is not 
common among Medicare beneficiaries.42 In addition, exam results are not available in 
Medicare claims and trends in blood pressure control could not be determined. Also, clinical 
considerations that lead to the initiation and use of antihypertensive medication are not 
available in claims data. Finally, we studied older Medicare beneficiaries and the 
generalizability of our findings to younger adults is unknown.
Future research should include interventions that are focused on populations at high risk for 
discontinuation and low adherence including racial/ethnic minorities, people with low 
income-status, and those with polypharmacy. Among racial/ethnic minorities, research 
should identify characteristics that may explain racial disparities in antihypertensive 
medication discontinuation and low adherence. Additionally, further investigating the 
association between incident development of co-morbid conditions and other characteristics 
with discontinuation and low adherence following initiation is warranted in order to provide 
information on which patient population may benefit from closer monitoring for low 
adherence and treatment discontinuation.
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While there was no change in the percentage of Medicare beneficiaries who discontinued 
antihypertensive medication in the year following treatment initiation from 2007 to 2012, the 
percentage of Medicare beneficiaries with low antihypertensive medication adherence 
declined over the study time period. However, a substantial percentage of Medicare 
beneficiaries initiating antihypertensive medication in 2012, approximately 50%, 
discontinued treatment or had low adherence. Data from the current study support the need 
for continued monitoring of antihypertensive medication adherence and interventions aimed 
at improving rates of discontinuation and low adherence in patients initiating 
antihypertensive medication.
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This study shows that rates of low adherence to antihypertensive medication have 
declined from 2007 to 2012 among older US adults. Additionally, approximately 50% of 
older US adults initiating antihypertensive medication have low adherence or discontinue 
treatment within one year.
What is Relevant
Low antihypertensive medication adherence is associated with uncontrolled blood 
pressure and increased risk for cardiovascular disease events. Several interventions have 
been tested in randomized trials with the goal of improving antihypertensive medication 
adherence. It is unclear whether these interventions have been translated into clinical 
practice and resulted in improved adherence rates. We identified sociodemographic and 
clinical conditions associated with antihypertensive medication discontinuation and low 
adherence in order to inform future medication adherence interventions.
Summary
This study suggests that efforts to improve antihypertensive medication adherence over 
the past several decades may have been translated into clinical practice. However, low 
adherence to antihypertensive medication remains common.
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Interval based proportion of days covered (PDC) calculation method for defining medication 
adherence among beneficiaries on one class of antihypertensive medication (Top Panel) and 
two or more classes of antihypertensive medication (Bottom Panel).
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Percentage of Medicare beneficiaries who discontinued and/or had low adherence to 
antihypertensive medication within one year of initiation in 2007 through 2012. 
Discontinuation was defined as having no days of supply for any antihypertensive 
medication class during the last 90 days of the 365 day follow-up period. Low adherence 
was defined as an interval-based proportion of days covered <80% during the 365 day 
follow-up period among beneficiaries who did not discontinue treatment.
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Table 2
Unadjusted and multivariable adjusted relative risks and 95% confidence intervals for antihypertensive 










  2007 1(ref) 1(ref) 1(ref)
  2008 1.07 (1.01–1.14) 1.09 (1.02–1.16) 1.08 (1.02–1.15)
  2009 1.11 (1.04–1.18) 1.13 (1.06–1.20) 1.12 (1.05–1.20)
  2010 1.04 (0.97–1.11) 1.07 (1.00–1.14) 1.06 (0.99–1.13)
  2011 1.03 (0.97–1.10) 1.08 (1.01–1.15) 1.07 (1.00–1.14)
  2012 1.01 (0.95–1.08) 1.06 (0.99–1.13) 1.05 (0.98–1.12)
Age, years
  65–69 1(ref) 1(ref) 1(ref)
  70–74 1.00 (0.95–1.06) 1.00 (0.95–1.05) 1.00 (0.95–1.05)
  75–79 0.98 (0.93–1.04) 0.98 (0.93–1.04) 0.98 (0.93–1.04)
  80–84 1.02 (0.96–1.08) 1.02 (0.96–1.09) 1.03 (0.97–1.09)
  85+ 1.00 (0.95–1.07) 1.02 (0.96–1.09) 1.03 (0.97–1.10)
Sex
  Male 1(ref) 1(ref) 1(ref)
  Female 0.89 (0.86–0.93) 0.87 (0.84–0.90) 0.87 (0.84–0.91)
Race/ethnicity
  White 1(ref) 1(ref) 1(ref)
  Black 1.08 (1.01–1.15) 1.07 (1.01–1.15) 1.07 (1.00–1.14)
  Hispanic 1.32 (1.21–1.44) 1.17 (1.06–1.28) 1.16 (1.06–1.27)
  Asian 1.25 (1.14–1.38) 1.12 (1.01–1.24) 1.12 (1.02–1.24)
  Other 1.13 (1.02–1.26) 1.11 (1.00–1.24) 1.11 (0.99–1.24)
Antihypertensive drug class
initiated
  Thiazide-type diuretic 0.94 (0.89–0.98) 1.16 (1.09–1.23) 1.15 (1.08–1.22)
  Calcium channel blocker 0.84 (0.80–0.89) 0.89 (0.84–0.93) 0.89 (0.84–0.93)
  Angiotensin converting
enzyme inhibitor
0.81 (0.78–0.85) 0.88 (0.84–0.91) 0.87 (0.83–0.90)
  Angiotensin receptor
blocker
0.83 (0.79–0.88) 0.85 (0.81–0.91) 0.86 (0.81–0.91)
  Loop diuretic 1.33 (1.27–1.40) 1.40 (1.32–1.47) 1.44 (1.36–1.52)
  Beta blocker 0.86 (0.83–0.90) 0.90 (0.87–0.95) 0.91 (0.87–0.95)
  Other 1.14 (1.08–1.22) 1.28 (1.20–1.36) 1.29 (1.21–1.37)
Single/Multiclass
  Single Class 1(ref) 1(ref) 1(ref)
  Multiclass/multiple pill 0.62 (0.57–0.66) 0.62 (0.58–0.67) 0.66 (0.61–0.71)
  Multiclass/Combination
therapy
0.80 (0.76–0.85) 0.84 (0.79–0.89) 0.84 (0.79–0.88)
Initiated with a 90 day fill 0.71 (0.68–0.75) 0.73 (0.70–0.77) 0.72 (0.69–0.76)































Medicaid buy-in 1.24 (1.19–1.29) 1.14 (1.09–1.19) 1.15 (1.10–1.21)
Dementia 0.96 (0.90–1.02) 0.89 (0.83–0.95) 0.92 (0.86–0.98)
Diabetes 1.02 (0.98–1.07) 1.00 (0.96–1.04) 1.02 (0.98–1.07)
Coronary heart disease 1.03 (0.99–1.08) 1.01 (0.97–1.06) 1.03 (0.99–1.09)
Stroke 0.87 (0.81–0.95) 0.85 (0.79–0.93) 0.87 (0.80–0.95)
Chronic kidney disease 1.02 (0.97–1.08) 1.00 (0.95–1.06) 1.02 (0.96–1.08)
Heart failure 0.96 (0.90–1.03) 0.97 (0.90–1.03) 0.99 (0.93–1.06)
History of depression 1.04 (1.00–1.09) 1.00 (0.96–1.05) 1.02 (0.98–1.07)
Falls 1.10 (1.01–1.19) 1.12 (1.03–1.21) 1.14 (1.05–1.24)
Polypharmacy 1.19 (1.14–1.24) 1.13 (1.07–1.18) 1.08 (1.02–1.14)
Medicare part D coverage
gap
1.10 (1.06–1.15) 1.00 (0.95–1.05) 0.98 (0.93–1.03)
Six months after initiation
Medicaid buy-in 0.87 (0.76–0.99) 0.95 (0.83–1.08)
Newly diagnosed dementia 0.84 (0.74–0.97) 0.88 (0.77–1.01)
Newly diagnosed diabetes 0.94 (0.81–1.07) 0.97 (0.84–1.11)
Newly diagnosed
coronary heart disease
0.91 (0.82–1.00) 0.94 (0.85–1.04)
Newly diagnosed stroke 0.82 (0.70–0.96) 0.83 (0.71–0.98)
Newly diagnosed chronic
kidney disease
0.94 (0.85–1.03) 0.99 (0.90–1.09)
Newly diagnosed heart
failure
0.36 (0.21–0.61) 0.38 (0.22–0.64)
Newly diagnosed depression 0.85 (0.78–0.92) 0.95 (0.87–1.03)
Falls 0.98 (0.85–1.13) 1.04 (0.90–1.19)
Polypharmacy 0.66 (0.62–0.71) 0.73 (0.68–0.79)
Medicare part D coverage
gap
0.71 (0.64–0.78) 0.76 (0.69–0.84)
RR=relative risk; CI=confidence interval.
Discontinuation was defined as having no days of supply for any antihypertensive medication class during the last 90 days of the 365 day follow-up 
period.
Multiclass=Incident prescription fill for ≥2 medications within 7 days.
Multivariable Adjusted 1: includes calendar year, age, race/ethnicity, sex, antihypertensive drug class initiated, and Medicaid buy-in, dementia, 
diabetes, coronary heart disease, stroke, chronic kidney disease, heart failure, history of depression, falls, polypharmacy, Medicare part D coverage 
gap from the year prior to antihypertensive medication initiation.
Multivariable Adjusted 2: includes variables in Model 1 and variables from the six months after antihypertensive medication initiation.
To avoid co-linearity, each antihypertensive medication class was evaluated in separate regression models with beneficiaries initiating an 
antihypertensive medication class being compared to beneficiaries initiating treatment without that class.
*
P-trend unadjusted =0.451; multivariable adjusted 1 =0.302; multivariable adjusted 2 =0.501
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Table 3
Unadjusted and multivariable adjusted relative risk and 95% confidence intervals for low adherence to 











  2007 1(ref) 1(ref) 1(ref)
  2008 0.96 (0.91–1.01) 0.97 (0.92–1.02) 0.97 (0.92–1.01)
  2009 0.97 (0.93–1.02) 0.99 (0.94–1.04) 0.99 (0.94–1.04)
  2010 0.94 (0.89–0.99) 0.96 (0.92–1.01) 0.96 (0.91–1.01)
  2011 0.89 (0.84–0.93) 0.93 (0.88–0.97) 0.92 (0.87–0.97)
  2012 0.85 (0.80–0.89) 0.89 (0.84–0.93) 0.88 (0.83–0.92)
Age, years
  65–69 1(ref) 1(ref) 1(ref)
  70–74 1.03 (0.98–1.07) 1.03 (0.99–1.07) 1.03 (0.98–1.07)
  75–79 1.02 (0.97–1.06) 1.03 (0.98–1.07) 1.02 (0.98–1.07)
  80–84 0.98 (0.94–1.03) 1.02 (0.97–1.07) 1.01 (0.96–1.06)
  85+ 0.93 (0.88–0.98) 1.00 (0.95–1.05) 0.99 (0.94–1.04)
Sex
  Male 1(ref) 1(ref) 1(ref)
  Female 0.97 (0.94–1.00) 0.96 (0.93–0.99) 0.96 (0.93–0.99)
Race/ethnicity
  White 1(ref) 1(ref) 1(ref)
  Black 1.37 (1.31–1.43) 1.37 (1.31–1.44) 1.36 (1.30–1.43)
  Hispanic 1.50 (1.41–1.61) 1.37 (1.28–1.47) 1.37 (1.28–1.47)
  Asian 1.21 (1.11–1.32) 1.10 (1.01–1.21) 1.11 (1.02–1.22)
  Other 1.21 (1.11–1.32) 1.18 (1.08–1.29) 1.18 (1.09–1.29)
Antihypertensive drug class
initiated
  Thiazide-type diuretic 1.05 (1.01–1.08) 1.10 (1.05–1.15) 1.09 (1.04–1.15)
  Calcium channel blocker 0.82 (0.80–0.85) 0.85 (0.82–0.89) 0.86 (0.82–0.89)
  Angiotensin converting
enzyme inhibitor
0.83 (0.79–0.86) 0.87 (0.84–0.90) 0.86 (0.84–0.89)
  Angiotensin receptor
blocker
1.13 (1.09–1.17) 1.10 (1.06–1.15) 1.11 (1.06–1.15)
  Loop diuretic 1.18 (1.12–1.23) 1.33 (1.26–1.39) 1.34 (1.28–1.41)
  Beta blocker 0.89 (0.86–0.92) 0.95 (0.92–0.99) 0.96 (0.92–0.99)
  Other 0.96 (0.91–1.02) 1.01 (0.95–1.07) 1.01 (0.96–1.07)
Single/Multiclass
  Single Class 1(ref) 1(ref) 1(ref)
  Multiclass/multiple pill 0.65 (0.62–0.69) 0.65 (0.61–0.69) 0.67 (0.63–0.71)
  Multiclass/Combination
therapy
1.00 (0.96–1.04) 1.01 (0.97–1.05) 1.01 (0.97–1.05)






























Initiated with a 90 day fill 0.77 (0.74–0.80) 0.78 (0.76–0.82) 0.78 (0.75–0.81)
Year before initiation
Medicaid buy-in 1.21 (1.17–1.25) 1.10 (1.06–1.14) 1.11 (1.07–1.15)
Dementia 0.76 (0.72–0.81) 0.73 (0.69–0.78) 0.76 (0.71–0.80)
Diabetes 1.04 (1.01–1.08) 1.02 (0.99–1.05) 1.04 (1.01–1.08)
Coronary heart disease 1.03 (0.99–1.07) 1.07 (1.03–1.11) 1.08 (1.04–1.13)
Stroke 0.87 (0.81–0.92) 0.88 (0.82–0.94) 0.89 (0.83–0.95)
Chronic kidney disease 1.02 (0.97–1.07) 1.03 (0.99–1.08) 1.05 (1.00–1.10)
Heart failure 0.94 (0.89–0.99) 0.97 (0.92–1.03) 0.99 (0.94–1.05)
History of depression 0.99 (0.96–1.02) 1.01 (0.97–1.04) 1.03 (0.99–1.07)
Falls 0.92 (0.86–0.99) 1.00 (0.93–1.07) 1.02 (0.95–1.10)
Polypharmacy 1.14 (1.10–1.18) 1.14 (1.09–1.18) 1.11 (1.06–1.16)
Medicare part D coverage
gap
0.99 (0.95–1.02) 0.92 (0.88–0.96) 0.89 (0.85–0.93)
Six months after initiation
Medicaid buy-in 0.91 (0.82–1.01) 0.98 (0.88–1.08)
Newly diagnosed dementia 1.03 (0.93–1.13) 0.98 (0.89–1.08)
Newly diagnosed diabetes 1.05 (0.95–1.17) 1.06 (0.95–1.17)
Newly diagnosed
coronary heart disease
0.99 (0.92–1.07) 1.01 (0.94–1.09)
Newly diagnosed stroke 1.12 (1.01–1.24) 1.11 (1.00–1.23)
Newly diagnosed chronic
kidney disease
1.02 (0.94–1.10) 1.04 (0.97–1.13)
Newly diagnosed heart
failure
1.10 (0.89–1.35) 1.11 (0.89–1.38)
Newly diagnosed depression 0.94 (0.88–1.00) 1.02 (0.96–1.09)
Falls 1.25 (1.14–1.38) 1.31 (1.19–1.44)
Polypharmacy 0.76 (0.72–0.80) 0.83 (0.78–0.87)
Medicare part D coverage
gap
0.72 (0.67–0.78) 0.74 (0.69–0.80)
RR=relative risk; CI=confidence interval.
Low adherence was defined as an interval-based proportion of days covered<80% during the 365 day follow-up period among beneficiaries who 
did not discontinue treatment.
Multiclass=Incident prescription fill for ≥2 medications within 7 days.
Multivariable Adjusted 1–includes calendar year, age, race/ethnicity, sex, antihypertensive drug class initiated, and Medicaid buy-in, dementia, 
diabetes, coronary heart disease, stroke, chronic kidney disease, heart failure, history of depression, falls, polypharmacy, Medicare part D coverage 
gap from the year prior to antihypertensive medication initiation.
Multivariable Adjusted 2–includes variables in Model 1 and variables from the six months after antihypertensive medication initiation.
To avoid co-linearity, each antihypertensive medication class was evaluated in separate regression models with beneficiaries initiating an 
antihypertensive medication class being compared to beneficiaries initiating treatment without that class.
*
P-trend unadjusted <0.001; multivariable adjusted 1 <0.001; multivariable adjusted 2 <0.001
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